Skip to main content

Advertisement

Neutralization of IL-17 ameliorates uveitis but damages photoreceptors in a murine model of spondyloarthritis

Arthritis Research & Therapyvolume 14, Article number: R18 (2012) | Download Citation

Abstract

Introduction

Uveitis, or intraocular inflammatory disease, is a frequent extra-articular manifestation of several forms of arthritis. Despite the frequent co-occurrence of uveitis and arthritis, little is understood of the eye's predisposition to this disease. We recently described a previously unreported uveitis in a murine model of spondyloarthropathy triggered by autoimmunity to aggrecan, a prominent proteoglycan (PG) macromolecule in cartilage. In contrast to the joint and spine, wherein interferon-gamma (IFNγ) deficiency reduced disease, IFNγ deficiency worsened uveitis. Given the regulatory role of IFNγ on the Th17 response and the current focus of anti-interleukin-17 therapeutics in patients with uveitis and spondyloarthritis, we sought to determine the extent to which interleukin (IL)-17 mediates uveitis in the absence of IFNγ.

Methods

Antigen specific T cell cytokine production was measured in splenocyte cultures using multiplex-ELISA. Transgenic (Tg) mice expressing the T cell receptor (TCR) recognizing the dominant arthritogenic epitope in the G1 domain of PG (TCR-Tg), also lacking IFNγ, were immunized with PG. Mice were then systemically administered an anti-IL-17 neutralizing antibody. The onset and severity of peripheral arthritis was evaluated by clinical scoring criteria and histology. Uveitis was assessed using intravital videomicroscopy, which visualizes leukocyte trafficking within the vasculature and tissue of the iris, and by histology.

Results

TCR-Tg splenocytes stimulated in vitro with recombinant G1 peptide demonstrated exacerbated production of cytokines, such as macrophage inflammatory protein (MIP)-1α, MIP-1β, IL-1β, and most notably IL-17A as a consequence of IFNγ deficiency. In vivo, IL-17 inhibition prevented the component of PG-induced arthritis that occurs independently of IFNγ. Blockade of IL-17 ameliorated the ongoing leukocyte trafficking responses within the iris vasculature and tissue, which coincided with reduced infiltration of leukocytes within the anterior and posterior eye segments. However, the anti-IL-17 treatment resulted in unanticipated photoreceptor toxicity.

Conclusions

These data support a protective, regulatory role for IFNγ in suppression of IL-17-mediated intraocular disease and to a lesser extent, joint disease. The unanticipated photoreceptor toxicity raises some caution regarding the use of anti-IL-17 therapeutics until the mechanism of this potential effect is determined.

Introduction

Uveitis, or intraocular inflammatory disease, is a leading cause of visual loss and the most common, clinically important extra-articular manifestation in several several diseases such as ankylosing spondylitis (AS), Behçet's disease, and juvenile idiopathic arthritis. Anterior uveitis, wherein the iris tissue is consistently affected, is the most frequently diagnosed type of uveitis in North America and Europe and occurs in as many as 50% of patients with AS [1, 2]. Despite the high incidence of uveitis with AS and its closely related spondyloarthropathies [3], the mechanism for their coexistence is not known. Indeed, uveitis has not been a reported feature in mouse models of arthritic disease.

We recently discovered that uveitis develops in a murine model of spondyloarthropathy that arises from autoimmunity to the cartilage proteoglycan (PG) aggrecan [4], which is a proposed potential autoantigen in AS [5]. Experimental PG-induced uveitis appears to replicate to some extent the spectrum of human uveitis that occurs in patients with spondyloarthritis. In this mouse model, disease is induced by immunization of genetically susceptible BALB/c mice with PG or its G1 domain [6]. A progressive and chronic erosive polyarthritis and axial spondylitis ensue [7–9]. PG-arthritis is a T cell-dependent disease [10] in which the Th1 effector response plays an important pathogenic role in the peripheral joint disease [11, 12]. Transgenic (Tg) mice expressing the T cell receptor (TCR) recognizing an arthritogenic epitope of PG (denoted here as TCR-Tg mice) develop an earlier onset and more severe form of polyarthritis than wild-type mice [13]. We previously reported an unexpected discordant mechanism of disease in the eyes versus joints with respect to interferon-gamma (IFNγ) in TCR-Tg mice. Mice deficient in IFNγ develop exacerbated uveitis that is characterized by infiltrating granulocytes, whereas the joint and axial disease are ameliorated by IFNγ deficiency [4].

The Th17 signaling axis has emerged as a potential therapeutic target, and anti-IL-17 therapy is currently under evaluation for spondyloarthritis and related diseases, including psoriatic arthritis, psoriasis, inflammatory bowel disease, Behçet's disease and uveitis [14, 15]. Given the counter-regulatory role for IFNγ on the Th17 responses, the present study was designed to examine whether the exacerbated uveitis that occurs in the absence of IFNγ results from an imbalance of the Th17 response. Here, we demonstrate that antigen-specific T cell production of IL-17A is exacerbated in the absence of IFNγ. The worsened uveitis that occurs in IFNγ KO mice is inhibited by in vivo blockade of IL-17. The remaining arthritis that ensues independently of IFNγ is further reduced as a consequence of IL-17 neutralization. However, our findings reveal unanticipated photoreceptor toxicity subsequent to the treatment with anti-IL-17 antibody, in that the photoreceptors are frequently obliterated. We conclude that IFNγ exerts a critical regulatory role in suppression of IL-17, which is pathogenic in uveitis. Our observations provide insight into a relatively common but poorly understood eye disease and could have potential dual clinical relevance as to how we approach anti-IL-17 therapeutics in patients with uveitis and spondyloarthritis.

Materials and methods

Mice, immunizations and treatment with anti-IL-17 antibody

TCR-Tg mice [13] that were backcrossed 10 generations onto a BALB/c background were inter-crossed with IFNγ KO mice on BALB/c background (The Jackson Laboratory, Bar Harbor, ME, USA); hereon abbreviated GKO/TCR-Tg mice. Housing and experimentation on mice was carried out under approval of the Oregon Health and Science University Animal Care and Use Guidelines. Female, 16-week-old mice were immunized intraperitoneally (i.p.) with 100 μg purified human cartilage PG in 200 μl phosphate-buffered saline (PBS, pH 7.4) emulsified with dimethyl dioctadecyl ammonium bromide (DDA; Sigma-Aldrich, St. Louis, MO, USA)), along with 1.5 μg pertussis toxin (Sigma). Mice received an additional i.p. injection of pertussis toxin 48 h later, as previously described [4, 16]. Control groups received PBS/DDA and pertussis toxin injections without PG antigen. For neutralization of IL-17, mice were administered an i.p. injection of 100 μg of anti-IL-17 (anti-IL-17A and IL-17A/F heterodimer; monoclonal rat IgG2a, clone # 50104) blocking antibody or 100 μg of rat IgG2a (isotype control antibody, IC; R&D Systems, Minneapolis, MN, USA)) at the time of PG-immunization and weekly thereafter. Mice were assessed weekly for clinical manifestations of peripheral arthritis in a masked fashion using an established scoring method as previously described [4, 16]. The scores ranged from 0 to 4 per paw based on swelling, redness, deformities and ankylosis. The data are represented as the cumulative score for all four paws, resulting in a maximum of 16 per mouse.

Intravital videomicroscopy

Intraocular inflammation of the iris vasculature and tissue in mice anesthetized with 1.7% isoflurane was video recorded as previously described [4, 17, 18]. Digital videos (10 sec each) of three independent regions of the iris were captured with a black and white video camera (Kappa Scientific, Gleichen, Germany) on an epifluorescence intravital microscope (modified Orthoplan; Leica, Wetzlar, Germany). Diameter and length of each vessel segment or iris tissue as well as leukocyte phenotype (that is, rolling, adhering, infiltrating) were quantified off-line using Image J analysis software available from NIH.

Histopathology and uveitis scoring

Eyes and decalcified knee joints were fixed and prepared for paraffin embedding, and 7 μm tissue sections were stained with hematoxylin and eosin (H&E) as previously reported [19, 20]. For uveitis assessment, eyes were sectioned through the pupillary-optic nerve axis at four different depths and three sections from each depth were examined by a masked observer. Leukocyte infiltration into the aqueous humor of the anterior segment and vitreous body of the posterior segment was quantified as the mean number of cells per section per eye. Structural, morphological and photoreceptor changes to the retina were also assessed using an ocular histopathology grading system, which is indicated as the "structural score" [4]. Both eyes in each mouse were assessed.

Antigen-specific in vitro splenocyte stimulation

Splenocytes collected from three individual TCR-Tg or GKO/TCR-Tg mice were plated (2 × 106 cells/ml) in 96-well plates (BD Biosciences, San Diego, CA, USA) as described [21], and cells were stimulated in quadruplicate wells with 20 μg/ml of purified recombinant human (rhG1) domain of aggrecan. Cytokines were measured in supernatants 48 h post stimulation with Luminex multiplex ELISA (Millipore, Bedford, MA, USA). Data were analyzed using BeadView Multiplex Analysis Software (version 1.0, Upstate Cell Signaling Solutions, Lake Placid, NY, USA)).

Statistical analysis

Data are represented as mean ± SEM. Experiments were reproduced at least twice. Means were compared and statistical differences were determined with two-way and one-way analysis of variance (ANOVA) with two-tailed, Students t-test post hoc analyses. For the nonparametric clinical arthritis scores and ocular histopathology scores, the Mann-Whitney U test was used (Prism; Graph Pad Software, La Jolla, CA, USA). Probability values < 0.05 were considered statistically significant.

Results

IFNγ is an essential protective factor against uveitis triggered by proteoglycan autoimmunity

As previously described [4], TCR-Tg mice lacking IFNγ (hereon abbreviated GKO/TCR-Tg) develop exacerbated uveitis, which is characterized by increased intravascular cell trafficking responses within the iris, increased glial activation and infiltration of granulocytes. We initially examined the effects of IFNγ deficiency on cytokine production in vitro in response to T cell stimulation with the arthritogenic G1 peptide of PG (Figure 1). Enhanced production of cytokines, such as the Th2-related eosinophilic cytokine, IL-5, as well as higher production of neutrophil chemokines (macrophage inflammatory protein (MIP)-1α and MIP-1β) occurred as a consequence of IFNγ-deficiency. This observation is consistent with the histopathology and predominance of neutrophils and eosinophils observed in uveitic eyes as previously reported in mice lacking IFNγ [4]. IL-1β and most notably IL-17A production were markedly enhanced, suggestive of a heightened Th17 response in the absence of IFNγ. Negligible amounts of IL-23p40 or IL-23p19 were detected (data not shown). The normally abundant IFNγ production (plotted on a separate axis, right panel) was abolished in GKO/TCR-Tg mice as expected. These data indicate that in the absence of endogenous IFNγ, IL-17 production is enhanced that could in turn mediate uveitis.

Figure 1
figure1

IFNγ-deficiency results in an altered cytokine profile including exacerbated IL-17A production. Antigen specific T cell cytokine production was measured in splenocyte cultures from TCR-Tg mice with intact IFNγ (WT) or TCR-Tg mice lacking IFNγ (IFNγ KO) that were stimulated with the arthritogenic G1 peptide carrying the TCR-specific epitiope. Cytokine levels in the supernatants were quantified by multiplex-ELISA (Luminex) at 48 h post stimulation. Data are the mean ± SEM of values combined from three independent experiments. * P < 0.05, ** P < 0.001, *** P < 0.0001 comparison between genotypes of G1-stimulated cells.

Full size image

PG-induced uveitis is dependent on IL-17 in the absence of IFNγ

Given the emerging data supporting a key role for IL-17 in patients with AS and related spondyloarthropathies [22, 23], we tested whether systemically administered blocking antibody to IL-17 would alter the onset and/or severity of uveitis occurring in the absence of IFNγ. Using intravital videomicroscopy, a technique that allows us to visualize ongoing cellular trafficking responses in vivo within the iris vasculature and tissue, we examined ocular inflammation at three weeks post immunization, which is a time previously established to consistently coincide with uveitis in this model [4]. As expected, mice that were immunized with adjuvant alone showed negligible ocular inflammation regardless of the antibody treatment (Figure 2A). In contrast, PG immunization of mice treated with the isotype-matched control antibody (IC) resulted in increased leukocyte rolling and adherence within the microvasculature of the iris (Figure 2A) and subsequent infiltration within the iris tissue itself (as depicted in images captured by intravital microscopy (Figure 2B). Neutralization of IL-17 in the PG-immunized mice had a profound impact on the cellular trafficking response, as all cellular responses (rolling, adherence and infiltration) in the iris were abolished.

Figure 2
figure2

Cellular trafficking responses exacerbated in the iris by IFNγ deficiency areabrogated by IL-17A blockade. (A) Weekly i.p. injections of anti-IL-17A blocking antibody or isotype-matched control antibody (IC) were administered into PG-immunized GKO/TCR-Tg mice. Adjuvant-immunized control mice were also administered the anti-IL-17A blocking antibody and IC. The leukocyte trafficking response within the iris was assessed by intravital microscopy at three weeks following PG-immunization. ** P < 0.001, *** P < 0.0001 comparison between treatments: anti-IL-17 and IC antibodies (n = 8 mice/adjuvant groups and n = 12 mice/PG-immunized groups). (B) Representative images captured by intravital videomicroscopy demonstrate the increased leukocyte infiltration within the iris tissue of PG-immunized, IC control mice, which is completely blocked by anti-IL-17A treatment.

Full size image

Histopathological examination revealed a near-complete absence of inflammation in both the anterior and posterior eye segments as a consequence of anti-IL-17 therapy (Figure 3). In PG-immunized mice treated with the isotype control antibody an increased presence of infiltrated leukocytes within the aqueous humor, iris, ciliary body, choroid and vitreous body is visualized (as depicted in representative images Figure 3A). Consistent with our prior report, retinal damage such as folding of the inner nuclear layer (INL) and outer nuclear layer (ONL) layers is also a pathological feature of uveitis in mice lacking IFNγ (Figure 3A), which is graded using a structural scoring system [4]. In contrast, blockade of IL-17 significantly diminished the number of cells in the aqueous humor of the anterior segment as well as the cells in the vitreous body of the posterior segment (Figure 3A, B). Likewise, IL-17 blockade abolished the retinal vasculitis and retinal folding found in several IFNγ-deficient mice with PG-induced uveitis (Figure 3C). Despite the abolishment of inflammatory changes in the posterior segment upon IL-17 inhibition, a near-complete ablation of the ONL and photoreceptor layer (PRL) was observed in 9 of the 16 eyes examined (indicated by brackets in Figure 3A). This damage would be expected to result in complete vision loss. As indicated by the brackets, there is a space where the ONL and photoreceptor layers would normally be present, but which are instead missing in PG-immunized mice treated with anti-IL-17A antibody. The depletion in these layers could be a consequence of prior toxicity or cellular death, which may be attributed to these mice having a higher disease structural score then most of the mice that had received isotype-matched control antibody (Figure 3C). We also observed two eyes with similar retinal toxicity in adjuvant-immunized mice that were treated with anti-IL-17 antibody as indicated in the clinical scores for structural changes (Figure 3C). These data support a pathogenic role for IL-17 in uveitis; but PG-induced inflammation also increases the susceptibility of the eyes to the anti-IL-17-induced retinal toxicity.

Figure 3
figure3

IL-17 inhibition prevents uveitis but results in photoreceptor toxicity. (A) PG-immunized GKO/TCR-Tg mice were administered weekly i.p. injections of anti-IL-17A blocking antibody or isotype-matched control antibody (IC). Control mice were immunized with adjuvant and the anti-IL-17A blocking antibody or IC. Histological assessment of uveitis was performed at three weeks post PG-immunization. Representative images of the anterior and posterior eye segments are shown. Increased leukocyte infiltration in IC control mice is indicated by arrows (two left panels) (H&E stain). The brackets on the far right panel (anti-IL-17 treated group) indicate the space where the ONL and photoreceptor layers would normally be present, but which are absent. Original magnification: 200X. AC, anterior chamber; Co, cornea; CB, ciliary body, Ir, iris; Li, limbus; Vi, vitreous, GCL, ganglion cell layer, INL, inner nuclear layer, ONL, outer nuclear layer, PRL, photoreceptor layer. (B) The infiltrating cells present within the aqueous humor of the anterior eye segment or vitreous body of the posterior eye segment were quantified. (C) Structural changes within the retina were scored in both eyes of each mouse. Data points represent individual eyes from each mouse. * P < 0.05 comparison between treatments: anti-IL-17A and IC antibodies (n = 7 mice/adjuvant groups; n = 9 mice/PG-immunized groups).

Full size image

IL-17 mediates arthritis in the absence of IFNγ

PG-induced peripheral arthritis is considered to be primarily a Th1 dependent disease that occurs independently of IL-17 [11, 24, 25]. We have confirmed the pathogenic role for IFNγ in promoting peripheral arthritis as well as axial disease in the TCR-Tg mice [4]. However, there is a precedent for IFNγ regulating the dependency of IL-17 in arthritis [26], and we demonstrate here that the arthritis ensuing in the absence of IFNγ in TCR-Tg mice is mediated by IL-17. PG-induced arthritis that was already attenuated by the absence of IFNγ was effectively prevented by anti-IL-17 (Figure 4A). The protective effects of IL-17 blockade observed clinically were corroborated by histological changes (Figure 4B), wherein the synovial inflammation and infiltrated leukocytes were reduced. These data support a combinatorial role for Th1 and Th17 responses in promoting arthritis while IFNγ suppresses uveitis through an IL-17-dependent mechanism.

Figure 4
figure4

IFNγ regulates the requirement for IL-17 in PG-induced arthritis. PG-immunized GKO/TCR-Tg mice were administered weekly i.p. injections of anti-IL-17A blocking antibody or isotype-matched control antibody (IC). Mice were also immunized with adjuvant along with anti-IL-17A blocking antibody and IC. The peripheral arthritis was assessed as a function of time. (A) Clinical arthritic scores in GKO/TCR-Tg mice treated with anti-IL-17A or IC; ** P < 0.001 comparison between anti-IL-17A and IC antibody treatments in PG-immunized mice (n = 8 mice/adjuvant groups and n = 12 mice/PG-immunized groups). (B) Representative histological images of arthritic knee joints of GKO/TCR-Tg mice treated with IC or anti-IL-17 at three weeks post immunization (F, femur; T, tibia).

Full size image

Discussion

Our prior data demonstrated an important protective role for IFNγ in uveitis in a murine model of progressive spondyloarthritis. Here, we tested the extent to which IL-17 mediates uveitis occurring in the absence of IFNγ. Antigen-specific T cell production of IL-17A was exacerbated in vitro as a consequence of IFNγ deficiency. Assessment of leukocyte trafficking within the iris microvasculature and tissue by intravital videomicroscopy in mice treated with anti-IL-17 neutralizating antibody revealed impaired intravascular responses, such as rolling and adherence that coincided with fewer infiltrating cells in the iris tissue. The histopathology demonstrated that IL-17 blockade significantly reduced the number of infiltrating leukocytes within the aqueous humor and vitreous body. The peripheral arthritis that accompanies PG-induced uveitis was also diminished in mice that received the anti-IL-17 blocking antibody. However, despite protective effects of IL-17 inhibition on PG-induced uveitis, unexpected retinal toxicity was observed. Collectively, our data support an important role for IL-17 in the pathogenesis of PG-induced uveitis, which is negatively regulated by IFNγ.

Uveitis encompasses a heterogeneous group of diseases, and even though it can arise from microbial or viral infection, it is frequently diagnosed in inflammatory diseases involving the joints, such as ankylosing spondylitis, juvenile idiopathic arthritis, Behçet's disease and many others. The underlying mechanisms that result in the co-existence of uveitis and arthritis/spondylitis are poorly understood. An important association exists between HLA-B27 and anterior uveitis in patients with ankylosing spondylitis. Approximately 90% of affected individuals have the inherited B27 allele [27], but HLA-B27 does not account for all of the genetic risk for disease, nor the extent to which it influences the onset and severity of uveitis versus spondyloarthritis. For example, HLA-B27 transgenic rats spontaneously develop spondyloarthropathy but do not develop uveitis [28, 29]. This underscores the complexity of multisystem, immune-mediated polygenic diseases, in which environmental factors and/or endogenous microflora can contribute to the pathogenesis of disease within the different target organs.

Although it is not known whether the pathogenic mechanisms in uveitis are the same as arthritis and/or spondylitis, we initially hypothesized that the underlying basic mechanisms would be shared between these two organs in mice immunized with PG. Somewhat paradoxically, however, we found that IFNγ deficiency reduced disease in the joint and spine but worsened disease in the eye [4]. The discordant effects of IFNγ underscore the complexity of how immune-mediated diseases target multiple organs differentially. This phenomenon has presented considerable challenges in the treatment of uveitis in patients with multisystem diseases, such as Behçet's disease or AS. For example, the TNFα inhibitor, etanercept, diminishes arthritic symptoms in a subgroup of patients with AS [30, 31], but it does not always have comparable beneficial effects for uveitis in the same patients [32]; or it can even lead to increased severity of uveitis [33]. Understanding the unique aspects of individually affected tissues is clearly pertinent to the design of optimal therapies.

The data presented here suggest that IFNγ is protective in the eye by virtue of being counter-regulatory to the IL-17 response. Studies with various KO mice or blocking antibodies have dissected the separate roles of Th1 and Th17 effector responses in the peripheral arthritis aspect of the PG-induced disease model [11, 24, 25], wherein IFNγ serves an an important regulatory role in arthritis [26]. These studies indicate a dominant pathogenic role for IFNγ and the Th1 effector response over that of the Th17 response in arthritis. We recently demonstrated a similar pathogenic role for IFNγ in peripheral arthritis and extended its contribution to the axial disease that develops in TCR-Tg mice [4]. Our findings would indicated that although the Th17 response is not considered critical in the development of PG-induced joint disease, it does appear to be a prevailing response contributing to uveitis.

Th17 cells have been reported to play a role in induction of the animal model of posterior uveitis, experimental autoimmune uveitis (EAU) [34] and have been implicated in uveitis clinically [35, 36]. IL-17 is thought to contribute to disease through its ability to promote recruitment and activation of neutrophils, which is consistent with our previously reported increase in granulocyte numbers in PG-immunized mice lacking IFNγ [4]. The production of IL-17 from T cells is well-described, yet additional cellular sources including γδ T cells, NKT cells, macrophages, mast cells and neutrophils may be just as important as the T cells [37–40]. Indeed, a recent report supports the role of innate immune cells rather than T cells in expression of IL-17 in the joints of patients with spondyloarthritis [41]. Thus, the pathology of uveitis observed in response to PG-immunization could involve coordinated events between the T cells of the Th1 and Th17 lineages and innate immune cells, which then propagate tissue damage within uveitic eyes. Future studies that compare the cytokine sources along with their targets within uveitic eyes versus the arthritic joints will be informative.

The IL-23/IL-17 axis is a major focus of spondyloarthritis research, and many pharmaceutical companies are actively working on strategies to block IL-17 in uveitis, AS and related spondyloarthropathies [14, 15, 36, 42]. Therefore, it is critical to understand how this cytokine can contribute to immune-mediated uveitis models in mice, and possibly in humans. Although reduced clinical signs of arthritis and ocular disease following anti-IL-17 treatment suggest great therapeutic potential for the use of this antibody, our observations of retinal toxicity indicate the need to proceed cautiously. We were unable to measure visual acuity, however the observed depletion of photoreceptors and ONL would be expected to result in near to complete vision loss. This observation brings to question why inhibition of IL-17 may result in toxicity within the eye. We are not aware of any reports that demonstrate a role or involvement of IL-17A in the survival of retinal cells. Nonetheless, a number of studies implicate IL-17A involvement in apoptotic or cell survival responses in different cell types and diseases [43–45], suggesting its potential role in cellular viability within the eye. Retinal toxicity derived from anti-IL-17 antibody treatments has not been previously reported in other murine uveitis models [34, 46, 47], indicating that the toxicity could possibly involve a combination of events within this particular disease model, such as glial cell activation within the retina, the presence of PG-antigen within the retina, and/or ongoing systemic disease [4]. At the time examined here (three weeks post PG-immunization), the photoreceptor toxicity did not coincide with increased expression of GFAP (glial fibrillary acidic protein, a marker of glial activation, data not shown). However, we cannot rule out the contribution of glial activation at times preceding photoreceptor toxicity. Studies are underway to elucidate whether inhibiting the Th17 response through targeting IL-17R or the upstream cytokine IL-23 reduces uveitis without photoreceptor damage. These studies would inform us to the potential toxicity effects of this particular antibody versus the contribution of the Th17 pathway in photoreceptor viability. The observations presented here yield valuable information regarding contrasting mechanisms of disease within different portions of the body and could have an impact on how we approach therapy in complex, inflammatory diseases.

Conclusions

The present study demonstrates an important regulatory role for IFNγ in uveitis associated with a murine model of spondyloarthropathy. Antigen-specific activation of naive TCR-Tg T cells lacking IFNγ in culture resulted in enhanced cytokine levels of IL-17A, which correlated with worsened uveitis but not arthritis in PG-immunized mice. Blockade of IL-17 in vivo ameliorated the ongoing cell trafficking responses within the iris vasculature and iris tissue, which coincided with diminished leukocyte accumulation within the aqueous humor and vitreous body. The residual arthritis ensuing in the absence of IFNγ was further reduced by anti-IL-17 neutralization. These data support a combinatorial role for Th1 and Th17 responses in arthritis, which is in opposition to the eye wherein we discovered a counter-regulatory role for Th1 and Th17 responses in uveitis. Despite the beneficial anti-inflammatory effects of the anti-IL-17 blocking antibody, caution must be exercised in developing anti-IL-17 therapeutics for uveitis due to the unexpected photoreceptor toxicity. Investigation of simultaneous eye and joint disease within a mouse could reveal important insights into how we approach therapy in uveitic patients with inflammatory diseases such as AS.

Abbreviations

AC:

anterior chamber

AS:

ankylosing spondylitis

CB:

ciliary body

Co:

cornea

DDA:

dimethyl dioctadecyl ammonium bromide

F:

femur

GCL:

ganglion cell layer

GKO/TCR-Tg mice:

TCR-Tg mice deficient in IFNγ

IC:

isotype control antibody

INL:

inner nuclear layer

i.p.:

intraperitoneal

Ir:

iris

Li:

limbus

ONL:

outer nuclear layer

PG:

the proteoglycan aggrecan

PRL:

photoreceptor layer

T:

tibia

TCR-Tg mice:

transgenic mice expressing the TCR for the arthritogenic epitope of PG

Vi:

vitreous

WT:

wild-type.

References

  1. 1.

    Nussenblatt RB: The natural history of uveitis. Int Ophthalmol. 1990, 14: 303-308. 10.1007/BF00163549.

  2. 2.

    Zeboulon N, Dougados M, Gossec L: Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis. 2008, 67: 955-959.

  3. 3.

    Braun J, Sieper J: Ankylosing spondylitis. Lancet. 2007, 369: 1379-1390. 10.1016/S0140-6736(07)60635-7.

  4. 4.

    Kezic JM, Davey MP, Glant TT, Rosenbaum JT, Rosenzweig HL: IFNγ regulates discordant mechanisms of uveitis versus joint and axial disease in a murine model resembling spondyloarthritis. Arthritis Rheum. 2011, [Epub ahead of print]

  5. 5.

    Zou J, Appel H, Rudwaleit M, Thiel A, Sieper J: Analysis of the CD8+ T cell response to the G1 domain of aggrecan in ankylosing spondylitis. Ann Rheum Dis. 2005, 64: 722-729. 10.1136/ard.2004.024455.

  6. 6.

    Glant TT, Radacs M, Nagyeri G, Olasz K, Laszlo A, Boldizsar F, Hegyi A, Finnegan A, Mikecz K: Proteoglycan-induced arthritis and recombinant human proteoglycan aggrecan G1 domain-induced arthritis in BALB/c mice resembling two subtypes of rheumatoid arthritis. Arthritis Rheum. 2011, 63: 1312-1321. 10.1002/art.30261.

  7. 7.

    Glant TT, Cs-Szabo G, Nagase H, Jacobs JJ, Mikecz K: Progressive polyarthritis induced in BALB/c mice by aggrecan from normal and osteoarthritic human cartilage. Arthritis Rheum. 1998, 41: 1007-1018. 10.1002/1529-0131(199806)41:6<1007::AID-ART7>3.0.CO;2-6.

  8. 8.

    Glant TT, Finnegan A, Mikecz K: Proteoglycan-induced arthritis: immune regulation, cellular mechanisms, and genetics. Crit Rev Immunol. 2003, 23: 199-250. 10.1615/CritRevImmunol.v23.i3.20.

  9. 9.

    Bardos T, Szabo Z, Czipri M, Vermes C, Tunyogi-Csapo M, Urban RM, Mikecz K, Glant TT: A longitudinal study on an autoimmune murine model of ankylosing spondylitis. Ann Rheum Dis. 2005, 64: 981-987. 10.1136/ard.2004.029710.

  10. 10.

    Buzas EI, Brennan FR, Mikecz K, Garzo M, Negroiu G, Hollo K, Cs-Szabo G, Pintye E, Glant TT: A proteoglycan (aggrecan)-specific T cell hybridoma induces arthritis in BALB/c mice. J Immunol. 1995, 155: 2679-2687.

  11. 11.

    Cao Y, Doodes PD, Glant TT, Finnegan A: IL-27 induces a Th1 immune response and susceptibility to experimental arthritis. J Immunol. 2008, 180: 922-930.

  12. 12.

    Finnegan A, Grusby MJ, Kaplan CD, O'Neill SK, Eibel H, Koreny T, Czipri M, Mikecz K, Zhang J: IL-4 and IL-12 regulate proteoglycan-induced arthritis through Stat-dependent mechanisms. J Immunol. 2002, 169: 3345-3352.

  13. 13.

    Berlo SE, Guichelaar T, Ten Brink CB, van Kooten PJ, Hauet-Broeren F, Ludanyi K, van Eden W, Broeren CP, Glant TT: Increased arthritis susceptibility in cartilage proteoglycan-specific T cell receptor-transgenic mice. Arthritis Rheum. 2006, 54: 2423-2433. 10.1002/art.22013.

  14. 14.

    Yeremenko N, Baeten D: IL-17 in spondyloarthritis: is the T-party over?. Arthritis Rheum. 2011, 13: 115-

  15. 15.

    Song IH, Poddubnyy D: New treatment targets in ankylosing spondylitis and other spondyloarthritides. Curr Opin Rheumatol. 2011, 23: 346-351. 10.1097/BOR.0b013e328346f7fb.

  16. 16.

    Glant TT, Mikecz K: Proteoglycan aggrecan-induced arthritis: a murine autoimmune model of rheumatoid arthritis. Methods Mol Med. 2004, 102: 313-338.

  17. 17.

    Rosenzweig HL, Martin TM, Jann MM, Planck SR, Davey MP, Kobayashi K, Flavell RA, Rosenbaum JT: NOD2, the gene responsible for familial granulomatous uveitis, is essential in a mouse model of muramyl dipeptide-induced uveitis. Invest Ophthalmol Vis Sci. 2008, 49: 1518-1524. 10.1167/iovs.07-1174.

  18. 18.

    Becker MD, Nobiling R, Planck SR, Rosenbaum JT: Digital video-imaging of leukocyte migration in the iris: intravital microscopy in a physiological model during the onset of endotoxin-induced uveitis. J Immunol Methods. 2000, 240: 23-37. 10.1016/S0022-1759(00)00165-4.

  19. 19.

    Rosenzweig HL, Jann MJ, Vance EE, Planck SR, Rosenbaum JT, Davey MP: Nucleotide-binding oligomerization domain 2 and Toll-like receptor 2 function independently in a murine model of arthritis triggered by intraarticular peptidoglycan. Arthritis Rheum. 2010, 62: 1051-1059.

  20. 20.

    Rosenzweig H, Galster K, Planck S, Rosenbaum JT: NOD1 expression in the eye and functional contribution to IL-1{beta} dependent ocular inflammation in mice. Invest Ophthalmol Vis Sci. 2009, 50: 1746-1753.

  21. 21.

    Rosenzweig HL, Jann MM, Glant T, Martin TM, Planck SR, Van Eden W, Van Kooten PJ, Flavell RA, Kobayashi K, Rosenbaum JT, Davey MP: Activation of nucleotide oligomerization domain 2 exacerbates a murine model of proteoglycan-induced arthritis. J Leukoc Biol. 2009, 85: 711-718. 10.1189/jlb.0808478.

  22. 22.

    Wendling D, Cedoz JP, Racadot E, Dumoulin G: Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine. 2007, 74: 304-305. 10.1016/j.jbspin.2006.11.005.

  23. 23.

    Wang X, Lin Z, Wei Q, Jiang Y, Gu J: Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis. Rheumatol Int. 2009, 29: 1343-1347. 10.1007/s00296-009-0883-x.

  24. 24.

    Finnegan A, Mikecz K, Tao P, Glant TT: Proteoglycan (aggrecan)-induced arthritis in BALB/c mice is a Th1-type disease regulated by Th2 cytokines. J Immunol. 1999, 163: 5383-5390.

  25. 25.

    Doodes PD, Cao Y, Hamel KM, Wang Y, Farkas B, Iwakura Y, Finnegan A: Development of proteoglycan-induced arthritis is independent of IL-17. J Immunol. 2008, 181: 329-337.

  26. 26.

    Doodes PD, Cao Y, Hamel KM, Wang Y, Rodeghero RL, Mikecz K, Glant TT, Iwakura Y, Finnegan A: IFN-gamma regulates the requirement for IL-17 in proteoglycan-induced arthritis. J Immunol. 2010, 184: 1552-1559. 10.4049/jimmunol.0902907.

  27. 27.

    Feltkamp TEW: HLA B27, acute anterior uveitis, and ankylosing spondylitis. Adv Inflamm Res. 1985, 9: 211-216.

  28. 28.

    Hammer RE, Maika SD, Richardson JA, Tang JP, Taurog JD: Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2 m: an animal model of HLA-B27-associated human disorders. Cell. 1990, 63: 1099-1112. 10.1016/0092-8674(90)90512-D.

  29. 29.

    Baggia S, Lyons J, Angell E, Barkhhizen A, Han YB, Planck SR, Taurog JD, Rosenbaum JT: A novel model of bacterially-induced acute anterior uveitis in rats and the lack of effect from HLA B27 expression. J Investig Med. 1997, 45: 295-301.

  30. 30.

    Zochling J, Van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC, Dijkmans B, Dougados M, Geher P, Inman RD, Khan MA, Kvien TK, Leirisalo-Repo M, Oliveieri I, Pavelka K, Sieper J, Stucki G, Sturrock RD, van der Linden S, Wendling D, Bohm H, van Royen BJ, Braun J, 'Assessment in AS' international working group, European League Against Rheumatism: ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2006, 65: 442-452. 10.1136/ard.2005.041137.

  31. 31.

    Sfikakis PP: The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun. 2010, 11: 180-210.

  32. 32.

    Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson MR, Whitcup SM, Rosenbaum JT: Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. 2001, 45: 252-257. 10.1002/1529-0131(200106)45:3<252::AID-ART257>3.0.CO;2-5.

  33. 33.

    Lim LL, Fraunfelder FW, Rosenbaum JT: Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 2007, 56: 3248-3252. 10.1002/art.22918.

  34. 34.

    Luger D, Silver PB, Tang J, Cua D, Chen Z, Iwakura Y, Bowman EP, Sgambellone NM, Chan CC, Caspi RR: Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med. 2008, 205: 799-810. 10.1084/jem.20071258.

  35. 35.

    Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, Nussenblatt RB, Gery I, Lee YS, Egwuagu CE: TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med. 2007, 13: 711-718. 10.1038/nm1585.

  36. 36.

    Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH, Psoriasis Study Group, Durez P, Tak PP, Gomez-Eino JJ, Rheumatoid Arthritis Study Group, Foster CS, Kim RY, Samson CM, Falk NS, Chu DS, Callanan D, Nguyen QD, Uveitis Study Group, Rose K, Haider A, Di Padova F: Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010, 2: 52ra72-10.1126/scitranslmed.3001107.

  37. 37.

    Cua DJ, Tato CM: Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol. 2010, 10: 479-489. 10.1038/nri2800.

  38. 38.

    Gaffen SL: Recent advances in the IL-17 cytokine family. Curr Opin Immunol. 2011, 23: 1-7. 10.1016/j.coi.2010.12.001.

  39. 39.

    Moran EM, Heydrich R, Ng CT, Saber TP, McCormick J, Sieper J, Appel H, Fearon U, Veale DJ: IL-17A expression is localised to both mononuclear and polymorphonuclear synovial cell infiltrates. PLos One. 2011, 6: e24048-10.1371/journal.pone.0024048.

  40. 40.

    Mills KH: Induction, function and regulation of IL-17-producing T cells. Eur J Immunol. 2008, 38: 2636-2649. 10.1002/eji.200838535.

  41. 41.

    Appel H, Maier R, Wu P, Scheer R, Hempfing A, Kayser R, Thiel A, Radbruch A, Loddenkemper C, Sieper J: Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther. 2011, 13: R95-10.1186/ar3370.

  42. 42.

    Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S, Kunynetz R, Kavanaugh A: Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009, 373: 633-640. 10.1016/S0140-6736(09)60140-9.

  43. 43.

    Zhu F, Wang Q, Guo C, Wang X, Cao X, Shi Y, Gao F, Ma C, Zhang L: IL-17 induces apoptosis of vascular endothelial cells - a potential mechanism for human acute coronary syndrome. Clin Immunol. 2011, 141: 152-160. 10.1016/j.clim.2011.07.003.

  44. 44.

    Cunnusamy K, Chen PW, Niederkorn JY: IL-17 promotes immune privilege of corneal allografts. J Immunol. 2010, 185: 4651-4658. 10.4049/jimmunol.1001576.

  45. 45.

    Kirshberg S, Izhar U, Amir G, Demma J, Vernea F, Beider K, Shlomai Z, Wald H, Zamir G, Shapira OM, Peled A, Wald O: Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression. PLoS One. 2011, 6: e24856-10.1371/journal.pone.0024856.

  46. 46.

    Zhang Z, Zhong W, Spencer D, Chen H, Lu H, Kawaguchi T, Rosenbaum JT: Interleukin-17 causes neutrophil mediated inflammation in ovalbumin-induced uveitis in DO11.10 mice. Cytokine. 2009, 46: 79-91. 10.1016/j.cyto.2008.12.019.

  47. 47.

    Jiang G, Ke Y, Sun D, Han G, Kaplan HJ, Shao H: Reactivation of uveitogenic T cells by retinal astrocytes derived from experimental autoimmune uveitis-prone B10RIII mice. Invest Ophthalmol Vis Sci. 2008, 49: 282-289. 10.1167/iovs.07-0371.

Download references

Acknowledgements

The authors are grateful to Jenna S. Clowers, Katie Dahlhausen and Stephanie Tarlow for their technical support along with Drs. Stephen R. Planck and Michael P. Davey for their critical discussions and review of the manuscript. This work was supported by NIH (NEI grants EY019020, EY010572 and EY019604). HLR also receives support from the American College of Rheumatology Research and Education Foundation Health Professional New Investigator Award and Research to Prevent Blindness Foundation. The authors would also like to thank the William C. Kuzell Foundation, the Stan and Madelle Rosenfeld Family Trust, and the William and Mary Bauman Foundation for their support.

Author information

Affiliations

  1. Casey Eye Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., Portland, OR, 97239, USA

    • Jelena M Kezic
    • , James T Rosenbaum
    •  & Holly L Rosenzweig

  2. JMK is now affiliated with Centre for Eye Research Australia, University of Melbourne, East Melbourne VIC, 3002 Australia; and Department of Anatomy and Developmental Biology, Monash University, Melbourne, VIC, Australia

    • Jelena M Kezic

  3. Departments of Biochemistry and Orthopedics, Rush University Medical Center, 1735 W. Harrison St., Chicago, IL, 60612, USA

    • Tibor T Glant

  4. Department of Medicine, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., Portland, OR, 97239, USA

    • James T Rosenbaum

  5. Department of Cell and Developmental Biology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., Portland, OR, 97239, USA

    • James T Rosenbaum

  6. Department of Molecular Microbiology and Immunology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., Portland, OR, 97239, USA

    • Holly L Rosenzweig

Authors

  1. Search for Jelena M Kezic in:

  2. Search for Tibor T Glant in:

  3. Search for James T Rosenbaum in:

  4. Search for Holly L Rosenzweig in:

Corresponding author

Correspondence to James T Rosenbaum.

Additional information

Competing interests

The authors declare they have no competing interests except for JTR, who has consulted for Novartis, Amgen, Genentech, Pfizer, Abbott, UBC, Xoma and Allergan.

Authors' contributions

JK carried out the experiments, participated in acquisition of the data, analysis and interpretation of the data, and the manuscript preparation. TG participated in the acquisition of in vitro data through provision of recombinant G1 domain, interpretation of data and helped to draft the manuscript. JR participated in the design of the study, interpretation of data, and manuscript preparation. HR conceived of the study, participated in the design, data analysis, interpretation and manuscript preparation. All authors read and approved the final manuscript.

Authors’ original submitted files for images

Below are the links to the authors’ original submitted files for images.

Authors’ original file for figure 1

Authors’ original file for figure 2

Authors’ original file for figure 3

Authors’ original file for figure 4

Rights and permissions

Reprints and Permissions

About this article

Keywords

  • Ankylose Spondylitis
  • Uveitis
  • Aqueous Humor
  • Outer Nuclear Layer
  • Peripheral Arthritis

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us